Sagimet Biosciences Denifanstat + Resmetirom MASH Combination EASL 2026 Posters (May 27): FASN Inhibitor + Madrigal's Rezdiffra as Combination MASH Therapy Test
Sagimet Biosciences presented two posters at EASL 2026 today on the combination of its denifanstat (FASN inhibitor small molecule) with Madrigal's Rezdiffra (resmetirom, thyroid hormone receptor β agonist) for MASH. The combination work tests whether layered MASH therapies producing complementary mechanism-of-action effects can outperform either monotherapy. Denifanstat inhibits fatty acid synthase — the enzyme producing the majority of newly synthesized fatty acids in the liver — reducing hepatic lipogenesis upstream of the inflammation and fibrosis cascade that resmetirom addresses through downstream thyroid-hormone-receptor mechanisms. The combination represents the broader trend of MASH-as-multi-mechanism-battleground that defines EASL 2026: GLP-1/glucagon peptides (pemvidutide, DA-1726, survodutide), RNAi (ARO-INHBE), thyroid hormone agonism (Rezdiffra), FASN inhibition (denifanstat), and galectin-3 inhibition (belapectin) all running parallel programs.